Analyst on Lilly's diabetes hope: "An extremely strong start"
![Photo: Sydbank/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14545177.ece/ALTERNATES/schema-16_9/doc7nfhny77xsp1mq2cg32l.jpg)
Eli Lilly is off to a strong start when it comes to marketing and selling Mounjaro (tirzepatide) as a type 2 diabetes treatment, assesses Søren Løntoft Hansen, an analyst at Danish bank Sydbank.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly surprises with Mounjaro Q3 sales
For subscribers